Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"Initial interim data from the Phase 1/2 study with STEM's HuCNS-SC cells in geographic atrophy age-related macular degeneration were extraordinarily encouraging." (7/31/14) StemCells Inc. - The Life Sciences Report Interview with Christopher James More >
Grant Zeng has more than 10 years' professional experience in equity research and analysis. He is currently a senior biotech analyst with Zacks Investment Research Inc., and has been with Zacks since March 2006. Before joining Zacks, Zeng worked for TheStreet.com as a biotech analyst from 2005-2006. From September 2001 to December 2003, Zeng worked for China Pacific Insurance Co. as an equity/fund analyst. Zeng was a healthcare equity analyst with Young & Partners LLC from August 2000 to September 2001. Zeng also has teaching and research experience in pharmaceutical science. Zeng obtained his master's of business administration with a major in finance in 2000 from McMaster University, Canada. He also holds a master's degree in biochemistry from the University of Western Ontario, Canada, and earned a master's degree in pharmacology and bachelor's degree in medicine from Second Military Medical University in China. Zeng is a Chartered Financial Analyst (CFA).
Build Biotech Wealth on Solid Platforms: Grant Zeng (4/17/14) Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular company has the potential to succeed in the fast-moving life sciences industry. In this interview with The Life Sciences Report, Zeng dissects his process and names 10 companies that have survived his exacting examination.
6 Biotechs with Staggering Potential: Grant Zeng (4/4/13) When it comes to picking biotech stocks, does a buyside perspective matter more than a sellside? Not according to Zacks Investment Research Analyst Grant Zeng, who has straddled the divide. What really matters is research of uncompromised quality. In this interview with The Life Sciences Report, Zeng offers a primer on what he looks for in a biotech investment, and names companies with the potential for big returns.
"The Abstral acquisition has transformed GALE from a development biotech company into a commercial organization." (4/4/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Grant Zeng More >
"I expect results from NBS' Phase 2 PreSERVE-AMI trial in Q4/14; that will be proof of concept for this approach." (9/10/14) NeoStem Inc. - The Life Sciences Report Interview with Vernon Bernardino More >